Anupam Rasayan Q1 FY27: Revenue up 36% to ₹667.5 Cr; LOI with BASQUEVOLT for $300M
Anupam Rasayan reported Q1 FY27 consolidated revenue of ₹667.5 Cr, up 36% YoY. EBITDA grew 35% to ₹174.9 Cr. The company commercialized ETFA using flow chemistry and signed an LOI with BASQUEVOLT, S.A. for potential revenue of $300 million over 10 years, expected commercialization in FY27. The acquisition of Bliss GVS Pharma is progressing.
The significant revenue growth, positive financial metrics, the world's first commercialization of a product using flow chemistry, and a substantial potential revenue opportunity from a new LOI indicate a high impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue and EBITDA, along with strategic partnerships and product development milestones, indicating positive business performance and future outlook.
Anupam Rasayan India Limited announced its financial results for the first quarter of FY27, reporting a consolidated total income of ₹6,675 million (₹667.5 crore), a significant year-on-year growth of 36%. This growth was primarily driven by new product commercialization and healthy demand across all segments.
Consolidated EBITDA for the quarter also saw a robust increase of 35% year-on-year, reaching ₹1,749 million (₹174.9 crore), with margins maintained at 26%. This reflects the company's ongoing focus on high-value products.
In terms of product development, the company added three new products in Q1FY27, expanding its portfolio to over 125 products. Notably, Anupam Rasayan became the world's first company to commercialize ETFA (Ethyl Trifluoroacetate) using flow chemistry. The Pharma segment added one new intermediate for a new drug, while the Performance Material segment introduced two new products for reinforced polyester and high-performance engineering fluids.
The company also highlighted strategic developments, including a Letter of Intent (LOI) signed with BASQUEVOLT, S.A., which represents a potential revenue opportunity of up to $300 million over a 10-year period, with expected commercialization in FY27. The acquisition of Bliss GVS Pharma is progressing as planned, aiming to strengthen Anupam's pharmaceutical platform.
Standalone results showed a total income of ₹3,349 million (₹334.9 crore), a 4% year-on-year growth, with EBITDA at ₹1,155 million (₹115.5 crore), up 17% year-on-year.
Anand S Desai, Managing Director, expressed satisfaction with the strong start to FY27, emphasizing the technological milestone of ETFA commercialization and the significant revenue potential from the BASQUEVOLT LOI. He also confirmed the progress of the Bliss GVS Pharma acquisition and expressed confidence in the company's future growth prospects, driven by its product pipeline, customer engagement, and innovation.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.